A double-blind, placebo-controlled study of memantine in the treatment of major depression. 2006

Carlos A Zarate, and Jaskaran B Singh, and Jorge A Quiroz, and Georgette De Jesus, and Kirk K Denicoff, and David A Luckenbaugh, and Husseini K Manji, and Dennis S Charney
Mood and Anxiety Disorders Program, National Institute of Mental Health, Department of Human Health Services, Bethesda, MD, USA. zaratec@mail.nih.gov

OBJECTIVE This study was designed to assess possible antidepressant effects of memantine, a selective N-methyl-D-aspartate (NMDA) receptor antagonist in humans. METHODS In a double-blind, placebo-controlled study, 32 subjects with major depression were randomly assigned to receive memantine (5-20 mg/day) (N=16) or placebo (N=16) for 8 weeks. Primary efficacy was assessed by performance on the Montgomery-Asberg Depression Rating Scale (MADRS). RESULTS The linear mixed models for total MADRS scores showed no treatment effect. CONCLUSIONS In an 8-week trial, the low-to-moderate-affinity NMDA antagonist memantine in doses of 5-20 mg/day was not effective in the treatment of major depressive disorder.

UI MeSH Term Description Entries
D008297 Male Males
D008559 Memantine AMANTADINE derivative that has some dopaminergic effects. It has been proposed as an antiparkinson agent. 1,3-Dimethyl-5-aminoadamantane,1-Amino-3,5-dimethyladamantane,Axura,D-145,D145,Ebixa,Memantin,Memantine Hydrochloride,Namenda,D 145
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D003865 Depressive Disorder, Major Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5) Depression, Involutional,Major Depressive Disorder,Melancholia, Involutional,Paraphrenia, Involutional,Psychosis, Involutional,Depressive Disorders, Major,Involutional Depression,Involutional Melancholia,Involutional Paraphrenia,Involutional Paraphrenias,Involutional Psychoses,Involutional Psychosis,Major Depressive Disorders,Paraphrenias, Involutional,Psychoses, Involutional
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Carlos A Zarate, and Jaskaran B Singh, and Jorge A Quiroz, and Georgette De Jesus, and Kirk K Denicoff, and David A Luckenbaugh, and Husseini K Manji, and Dennis S Charney
January 2019, Journal of clinical psychopharmacology,
Carlos A Zarate, and Jaskaran B Singh, and Jorge A Quiroz, and Georgette De Jesus, and Kirk K Denicoff, and David A Luckenbaugh, and Husseini K Manji, and Dennis S Charney
January 2014, Journal of affective disorders,
Carlos A Zarate, and Jaskaran B Singh, and Jorge A Quiroz, and Georgette De Jesus, and Kirk K Denicoff, and David A Luckenbaugh, and Husseini K Manji, and Dennis S Charney
June 2014, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences,
Carlos A Zarate, and Jaskaran B Singh, and Jorge A Quiroz, and Georgette De Jesus, and Kirk K Denicoff, and David A Luckenbaugh, and Husseini K Manji, and Dennis S Charney
July 1992, Arzneimittel-Forschung,
Carlos A Zarate, and Jaskaran B Singh, and Jorge A Quiroz, and Georgette De Jesus, and Kirk K Denicoff, and David A Luckenbaugh, and Husseini K Manji, and Dennis S Charney
February 1997, Journal of clinical psychopharmacology,
Carlos A Zarate, and Jaskaran B Singh, and Jorge A Quiroz, and Georgette De Jesus, and Kirk K Denicoff, and David A Luckenbaugh, and Husseini K Manji, and Dennis S Charney
December 2004, Archives of general psychiatry,
Carlos A Zarate, and Jaskaran B Singh, and Jorge A Quiroz, and Georgette De Jesus, and Kirk K Denicoff, and David A Luckenbaugh, and Husseini K Manji, and Dennis S Charney
January 2016, Headache,
Carlos A Zarate, and Jaskaran B Singh, and Jorge A Quiroz, and Georgette De Jesus, and Kirk K Denicoff, and David A Luckenbaugh, and Husseini K Manji, and Dennis S Charney
January 1997, European psychiatry : the journal of the Association of European Psychiatrists,
Carlos A Zarate, and Jaskaran B Singh, and Jorge A Quiroz, and Georgette De Jesus, and Kirk K Denicoff, and David A Luckenbaugh, and Husseini K Manji, and Dennis S Charney
November 2001, International clinical psychopharmacology,
Carlos A Zarate, and Jaskaran B Singh, and Jorge A Quiroz, and Georgette De Jesus, and Kirk K Denicoff, and David A Luckenbaugh, and Husseini K Manji, and Dennis S Charney
April 2000, Journal of clinical psychopharmacology,
Copied contents to your clipboard!